LEXICON PHARMACEUTICALS ($LXRX) posted quarterly earnings results on Wednesday, August 6th. The company reported earnings of $0.01 per share, beating estimates of -$0.08 by $0.09. The company also reported revenue of $28,870,000, beating estimates of $4,964,850 by $23,905,150.
You can see Quiver Quantitative's $LXRX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LEXICON PHARMACEUTICALS Hedge Fund Activity
We have seen 65 institutional investors add shares of LEXICON PHARMACEUTICALS stock to their portfolio, and 68 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIREN, L.L.C. removed 35,402,689 shares (-91.0%) from their portfolio in Q1 2025, for an estimated $16,313,559
- FMR LLC removed 17,427,258 shares (-33.5%) from their portfolio in Q1 2025, for an estimated $8,030,480
- POINT72 ASSET MANAGEMENT, L.P. removed 8,988,421 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $4,141,864
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 6,143,300 shares (-93.0%) from their portfolio in Q1 2025, for an estimated $2,830,832
- NEA MANAGEMENT COMPANY, LLC removed 2,382,286 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,097,757
- CIBC PRIVATE WEALTH GROUP LLC added 2,240,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $1,032,192
- GSA CAPITAL PARTNERS LLP added 2,023,167 shares (+250.5%) to their portfolio in Q2 2025, for an estimated $1,913,309
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
LEXICON PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $LXRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/24/2025
- Piper Sandler issued a "Overweight" rating on 03/07/2025
To track analyst ratings and price targets for LEXICON PHARMACEUTICALS, check out Quiver Quantitative's $LXRX forecast page.
LEXICON PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $LXRX recently. We have seen 3 analysts offer price targets for $LXRX in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $4.0 on 06/24/2025
- Yasmeen Rahimi from Piper Sandler set a target price of $6.0 on 03/07/2025
- Roanna Ruiz from Leerink Partners set a target price of $1.0 on 03/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
